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results indicate that PCLS may represent a physiological 
and valuable model to identify cholestatic drugs and pro-
vide insight into the mechanisms underlying DIC.
Keywords Drug-induced cholestasis · Precision-cut liver 
slices · Bile acids · Drug-induced liver injury
Introduction
Drug-induced liver injury (DILI) is one of the main rea-
sons of drugs being excluded during the drug-development 
process or withdrawn from the market (Yang et al. 2013). 
Therefore, many efforts have been made to select reliable 
biomarkers and develop predictive in vitro models to detect 
hepatotoxic effects as early as possible in the drug-develop-
ment process.
Drug-induced cholestasis (DIC) is the leading and one 
of the most severe manifestations of DILI (Qiu et al. 2016). 
Cholestasis is characterized by a reduction in bile flow 
and can be caused by a variety of intra- or extra-hepatic 
mechanisms. Numerous drugs have been identified as a 
potentially cholestatic compound. And even though drugs 
undergo a screening for inducing cholestatic disorders 
in the pre-clinical and clinical phases, in many cases the 
occurrence of DIC is only being reported when the drug 
has been approved for registration and is administrated 
to thousands of patients. This is due to the fact that exact 
underlying mechanisms for DIC are not clear yet, hamper-
ing the validation of predictive biomarkers. At this moment 
there are no specific, highly predictive biomarkers for DIC 
(Padda et  al. 2011). Elevations in the systemic blood lev-
els of liver enzymes (such as alkaline phosphatase (ALP) 
and gamma-glutamyl transpeptidase (GGT)), bilirubin and 
bile acid (BA) are the most commonly used biomarkers in 
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application of rat precision-cut liver slices (PCLS) to pre-
dict DIC, using several biomarkers of cholestasis: hepato-
cyte viability, intracellular accumulation of total as well as 
individual bile acids and changes in the expression of genes 
known to play a role in cholestasis. Rat PCLS exposed to 
the cholestatic drugs chlorpromazine, cyclosporine A and 
glibenclamide for 48 h in the presence of a 60 μM physi-
ological bile acid (BA) mix reflected various changes asso-
ciated with cholestasis, such as decrease in hepatocyte via-
bility, accumulation and changes in the composition of BA 
and changes in the gene expression of Fxr, Bsep and Ntcp. 
The toxicity of the drugs was correlated with the accumula-
tion of BA, and especially DCA and CDCA and their con-
jugates, but to a different extent for different drugs, indicat-
ing that BA toxicity is not the only cause for the toxicity of 
cholestatic drugs. Moreover, our study supports the use of 
several biomarkers to test drugs for DIC. In conclusion, our 
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the clinic to identify cholestatic injury (Padda et al. 2011; 
Schadt et  al. 2016; Yang et  al. 2013). However, elevation 
in ALP and GGT are also observed during other liver dis-
eases and their elevation during intra-hepatic cholestasis 
sometimes is minor. Also, an elevation in the circulat-
ing BA concentration is not always associated with DILI 
(Rodrigues et al. 2014), and, on the other hand, some drugs 
cause asymptomatic cholestasis with respect to BA, where 
elevation in the enzymes is the only symptom (Padda et al. 
2011).
One of the most common causes of drug-induced choles-
tasis is the inhibition of the bile salt export pump (ABCB11 
or BSEP) (Yang et al. 2013). BSEP is responsible for the 
excretion of the recirculated as well as newly synthesized 
BA from the hepatocytes into the bile canaliculi. There-
fore, the inhibition of this transporter leads to the accumu-
lation of BA in hepatocytes, which is believed to be one 
of the main causes of the hepatotoxicity observed during 
cholestasis.
Prediction of cholestatic side effects of drugs relies 
mainly on animal experiments using the same biomark-
ers as described for patients, with the same drawbacks. 
Moreover, these in  vivo experiments do not provide any 
mechanistic insight, but do cause high animal discomfort. 
Thus, in  vitro tests with high predictive value that also 
provide insight into the mechanism are highly needed. 
Some in vitro models have been developed to predict drug-
induced cholestasis, based on hepatocyte sandwich mono-
cultures (Chatterjee et  al. 2014a, b; Oorts et  al. 2016). 
However, the decrease in drug-metabolizing enzyme activi-
ties and the variation in the expression of drug transport-
ers during culture, affects the predictivity and reliability of 
this model. Moreover, when cell viability is used as read-
out parameter for DIC, it should be realized that various 
liver toxicity mechanisms require the presence of other cell 
types besides hepatocytes and, therefore, cannot be prop-
erly predicted by monocultures. It has been recognized that 
drug-induced cholestasis is a multifactorial process, where 
cholestasis might be a primary as well as a secondary event 
leading to hepatotoxicity (Rodrigues et  al. 2014). These 
are so-called mixed cholestatic and hepatocellular injuries, 
where various liver cell types are involved (Padda et  al. 
2011; Schadt et  al. 2016). Furthermore, bile acid homeo-
stasis itself is a complex process that involves not only 
hepatocytes, but also other cell types, for example, cholan-
giocytes. Therefore, models that include various liver cell 
types would be of added value.
Precision-cut liver slices (PCLS) have been recog-
nized as a reliable and predictive ex vivo model for many 
toxicological and pharmacological studies (de Graaf et al. 
2010; Vickers and Fisher 2013). Advantages of this model 
include the presence of all liver cell types in their natural 
environment and physiological polarized expression of 
membrane transporters. Previous studies have shown that 
transcriptomics analysis of PCLS exposed to various chole-
static drugs successfully detected liver toxicity processes 
associated with cholestasis (Szalowska et al. 2013; Vatakuti 
et al. 2016). However, the direct measurement of total intra-
cellular bile acid concentrations has not been successfully 
performed, even though it might be an important biomarker 
in predicting drug–bile acid interactions (Yang et al. 2013). 
Therefore, in the present study we aimed to investigate 
whether PCLS reflect pathological changes related to chol-
estasis and thus can be used to predict DIC. We evaluated 
several biomarkers of cholestasis such as hepatocyte viabil-
ity, intracellular accumulation of bile acids and changes in 
the expression of genes known to play a role in cholestasis. 
For that, we exposed rat PCLS to different concentrations 
of three well-known cholestatic drugs: chlorpromazine 
(CP), cyclosporine A (CS), and glibenclamide (GB), in 
the presence of a physiological concentration of a bile acid 
mix mimicking the bile acid concentration and composition 
in the rat portal vein. The addition of BA to the medium 
is essential to allow BA to reach toxic intracellular levels 
upon BSEP inhibition, especially when BA-induced toxic-
ity is an endpoint. Several recent studies on sandwich-cul-
tured hepatocytes (SCH) showed that it was only possible 
to detect toxicity of cholestatic drugs, when BA was added 
to the culture medium (Chatterjee et  al. 2014b; Ogimura 
et  al. 2011). The relevance and predictivity of PCLS for 
DIC was shown by assessing the potential of the com-
pounds to cause cholestasis ex vivo by disturbing the BA 
homeostasis and by demonstrating a correlation between 
BA accumulation and viability.
Materials and methods
Animals
Male Wistar rats (weight 250–300 g) were obtained from 
Charles River (Sulzfeld, Germany). Animals were housed 
in a temperature- and humidity-controlled room on a 12-h 
light/dark cycle with food and tap water ad libitum (Har-
lan Laboratories B.V., Horst, The Netherlands). The rats 
were allowed to acclimatize for at least 7 days before start-
ing the experiments. All experiments were started between 
9.00 and 10.00 am to avoid influence of diurnal rhythm. All 
experiments were approved by the Animal Ethical Commit-
tee of the University of Groningen.
Excision of rat liver
The liver was excised under isofluorane/O2 anesthesia and 
placed into ice-cold University of Wisconsin (UW) organ 
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preservation solution (DuPont Critical Care, Waukegab, 
IL) until use.
Preparation and incubation of rat PCLS
PCLS were prepared as described previously by de Graaf 
et  al. with minor modifications (de Graaf et  al. 2010). In 
brief, PCLS of 5 mm in diameter, about 250 µm in thick-
ness and approximately 5 mg wet weight were used in this 
study. To get rid of cell debris and restore the ATP levels 
after the slicing procedure, the slices were pre-incubated 
for 1 h at 37 °C in a 12-well plate filled with 1.3 ml of Wil-
liams’ medium E (WME) (Life Technology) saturated with 
80%O2/5%CO2/15%N2 and supplemented with 25  mM 
glucose and 50 µg/ml gentamycin (Invitrogen), while gen-
tly shaking 90 times per minute. Afterwards, PCLS were 
transferred to another 12-well plate filled with 1.3  ml of 
medium with or without the 60 μM bile acid mix (compo-
sition of BA mix is given in Table 1) in combination with 
CP [18, 27 or 36 μM], CS [1, 3 or 5 μM], GB [120, 150 or 
180 μM] or the solvent DMSO (concentration during incu-
bation ≤0.5%) and incubated for 48 h. Non-toxic, low and 
medium toxic concentrations of drugs were chosen based 
on recently published results (Vatakuti et  al. 2015) and 
results from pilot experiments, which showed very steep 
concentration–effect curves (data not shown). Medium was 
refreshed after 24 h of incubation with medium containing 
the same initial drug concentration.
ATP and protein content of PCLS
Viability of PCLS was determined after 48-h incubation 
by means of the ATP content as described previously using 
the ATP Bioluminescence Assay Kit CLS II (Roche, Man-
nheim, Germany) (de Graaf et al. 2010). Protein content of 
the hPCLS was measured using the Bio-Rad DC Protein 
Assay (Bio-Rad, Munich, Germany) using a bovine serum 
albumin calibration curve as described (Starokozhko et al. 
2015).
LDH leakage
LDH leakage from the slice to the medium was used as 
a marker of cell damage. In brief, medium was collected 
after 24- and 48-h incubation, and stored at 4 °C until anal-
ysis (maximum 1  week). The LDH assay was performed 
using the Cyto Tox-ONE Homogenous Membrane Integ-
rity Assay kit (Promega, Madison, USA) according to the 
manufacturer’s instructions with slight modifications. In 
brief, 50 µL of medium sample was mixed with 50 µL of 
the substrate mix in a black 96-well plate. The plate was 
kept for 10 min in the dark and the stop reagent was added 
afterwards to the mixture. Fluorescence was read immedi-
ately at excitation 560 nm and emission 590 nm.
Total bile acid assay (TBA)
It is expected that in PCLS a part of the total BA pool 
resides in bile canaliculi. Therefore, to measure the intra-
cellular concentration of bile acids in the slices, an extra 
washing step to empty the bile canaliculi was performed 
before collecting PCLS for the TBA analysis. After 48 
h of incubation, the PCLS were transferred to another 
12-well plate containing 1.3 ml of  Ca2+-free and  Mg2+-free 
Hank’s Balanced Salt Solution (HBSS) (Life Technology) 
saturated with 90%  O2/5%  CO2/5%N2, supplemented with 
5  mM EGTA (Titriplex VI, Merck, Germany) and were 
incubated for 1h at 4 °C while gently shaking 90 times per 
minute. Pilot experiments showed that the concentration of 
BA in the slices gradually decreased during washing up to 
2 h in  Ca2+-free and  Mg2+-free HBSS with EGTA, with a 
minimum after 1 h, suggesting that a part of the BA resided 
in bile canaliculi formed by tight hepatocyte junctions that 
are sensitive to  Ca2+-depletion, which can be released after 
1-h incubation in  Ca2+ and  Mg2+-free conditions. There-
fore, a washing step of 1  h in  Ca2+-free and  Mg2+-free 
HBSS with EGTA was chosen as the most optimal. After 
this washing step, the slices were collected and stored in 
−80 °C until analysis. In those experimental groups where 
bile acids were not added to the medium, 3 slices were 
pooled together for the analysis, as the bile acid content of 
one slice was below the detection limit. In experimental 
groups with the addition of bile acids to the medium, indi-
vidual slices were collected in separate 1.5-ml Eppendorf 
tubes. Collected PCLS were homogenized for 45 s in 450 
μL of 70% methanol and centrifuged for 15  min at 15 °C 
and 13,000  rpm. The supernatant (350 μL) was collected 
to a new microcentrifuge tube and the pellet was used for 
Table 1  Composition of rat bile acid mix
Composition of bile acids Final concentration in the 
incubation medium (μM)
Cholic acid (CA) 33.24
Chenodeoxycholic acid (CDCA) 1.62
Deoxycholic acid (DCA) 0.88
Lithocholic acid (LCA) 0.04
Glycocholic acid (GCA) 0.63
Taurocholic acid (TCA) 8.92
Ursodeoxycholic acid (UDCA) 0.55
Taurochenodeoxycholic acid (TCDCA) 1.55
Taurohyodeoxycholic acid (THDCA) 6.37
Hyodeoxycholic acid (HDCA) 5.33
Glycoursodeoxycholic acid (GUDCA) 0.11
Taurodeoxycholic acid (TDCA) 0.68
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further protein analysis. The TBA concentration in the 
sample was measured using Total Bile Acids Assay Kit 
(Diazyme, USA) according to the manufacturer’s instruc-
tions with slight modifications. The collected supernatant 
was evaporated at 35 °C using the CentriVap Concentrator 
(Labconco, USA) and the formed sample pellet contain-
ing bile acids was reconstituted in 70 μL of Milli-Q water 
and stored at −20 °C until analysis. After thawing, 5  μL 
of the sample was mixed with 135 μL of the Thio-NAD 
(>0.1 mM) buffer in a clear 96-well plate and incubated in 
the dark at 37 °C for 3 min. Subsequently, 45 μL of the 3-α-
HSD (>2  kU/L), NADH (>0.1  mM) buffer was added to 
each well and the absorbance was read at 37 °C after 5 and 
30 min at 405 nm. TBA concentration in the sample was 
calculated using the equation provided in the kit using con-
jugated cholic acid as a standard.
Determination of individual bile acid concentrations 
by LC/MS
The concentration of DCA and CDCA, TDCA, GDCA, 
TCDCA, GCDCA. TCA and GCA was determined via 
LC-MS/MS in the same samples as used for the TBA assay 
and in appropriate calibration samples, using an Acquity 
UPLC system (Waters, Milford, MA, USA) coupled to a 
Xevo TQ-S (Waters) triple quadrupole mass spectrometer. 
The compounds were separated using a Zorbax Eclipse 
Plus C18 analytical column (Rapid Resolution HD 1.8 μm; 
50 × 2.1  mm, Agilent, USA). The elution gradient was as 
follows: 0 min 30% B; 2–2.5 min 80% B; and 2.6–4 min 
30% B. Solvent A consisted of 0.1% formic acid in water 
and Solvent B consisted of 0.1% formic acid in acetoni-
trile. The column temperature was set at 40 °C, and the 
flow rate was 500 µl/min. The effluent from the UPLC was 
passed directly into the electrospray ion source. Negative 
electrospray ionization was achieved using nitrogen as a 
desolvation gas with ionization voltage at 3.0 kVolt. The 
source temperature was set at 500 °C and argon was used 
as collision gas. Detection of the bile acids was based on 
isolation of the deprotonated molecular ion, [M–H]− after 
which MS/MS fragmentations and multi reaction monitor-
ing (MRM) were carried out. The following MRM transi-
tions were used: for TDCA and TCDCA m/z 498.1(parent 
ion) to m/z 498.1 and 80.2 (both product ions), for GDCA 
m/z 448.3(parent ion) to m/z 448.3 and 74.0 (both product 
ions), for GCDCA m/z 448.3(parent ion) to m/z 386.8 and 
74.0 (both product ions), for DCA m/z 391.2(parent ion) 
to m/z 391.2 and 345.0 (both product ions), for CDCA m/z 
391.2(parent ion) to m/z 391.2 and 373.2 (both product 
ions), for TCA m/z 514.1(parent ion) to m/z 514.1 and 80.2 
(both product ions), for GCA m/z 464.2(parent ion) to m/z 
464.2 and 73.9 (both product ions).
RNA isolation and cDNA synthesis
RNA isolation from the slices was performed using the 
 Maxwell® 16 LEV Total RNA purification kit (Promega, 
The Netherlands) with a  Maxwell® 16 LEV Instrument. 
After isolation, the RNA quality fulfilled the criteria of a 
260/280 ratio of ~2 and 260/230 ratio of 2.0–2.2. The con-
centration was measured using the ND-100 spectrophotom-
eter (Fisher Scientific, The Netherlands). TaqMan reverse 
Transcription Reagents Kits (Applied Biosystems, Foster 
City, CA) were used to generate cDNA from RNA. cDNA 
was generated in the Eppendorf master cycler (Hamburg, 
Germany) with the gradient at 20 °C for 10 min, 42 °C for 
30  min, 20 °C for 12  min, 99 °C for 5  min and 20 °C for 
5 min. RT-PCR was used to determine relative Bsep, Fxr 
and Ntcp mRNA expression levels. Primers used: Bsep, 
5′-TGG AAA GGA ATG GTG ATG GG-3′(F), 3′-CAG AAG 
GCC AGT GCA TAA CAGA-5′(R); Fxr: 5′-CCA ACC TGG 
GTT TCT ACC C-3′(F), 3′-CAC ACA GCT CAT CCC CTT 
T-5′(R); Ntcp; 5′-CTC CTC TAC ATG ATT TTC CAG CTT 
G-3′(F), 3′-CGT CGA CGT TCG TTC CTT TTC TTG -5′(R). 
RT-PCR was performed using SYBR Green with the ABI 
Prism 7900HT sequence detection system with 1 cycle of 
10 minutes at 95 °C, 40 cycles of 15  s at 95 °C and 25  s 
at 60 °C, with a dissociation stage (15  s at 95, 60 and 
95 °C). Sample Ct values were normalized using Gapdh 
as a housekeeping gene (5′-CGC TGG TGC TGA GTA TGT 
CG-3′(F), 3′-CTG TGG TCA TGA GCC CTT CC-5′(R)). The 
melt curve analysis was used to assess whether a single 
product was produced after RT-PCR. Data are expressed as 
a fold change compared to the non-treated control after 48 
h of incubation.
Statistics
A minimum of three different rat livers were used for each 
experiment, using slices in triplicates from each liver. Sta-
tistical testing was performed with two-way repeated meas-
ures ANOVA with individual rats as random effect. We 
performed a Tukey HSD post hoc test for pairwise com-
parisons. Correlation coefficients were calculated using 
Pearson’s R. A p value of ≤0.05 was considered to be sig-
nificant. In all graphs the mean values and standard error of 
the mean (SEM) are shown.
Results
Viability of PCLS upon drug exposure
The viability of PCLS following 48-h incubation with 
cholestatic drugs in the presence or absence of the BA mix 
was assessed by analysis of ATP content and LDH leakage 
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to the incubation medium. The BA mix itself did not sig-
nificantly decrease the ATP content of PCLS after 48 h 
(Fig. 1a–c). However, the LDH leakage increased slightly 
but significantly in the presence of BA (Fig. 1d–f). Addi-
tion of BA to the incubation medium increased the toxic-
ity of the higher doses of CP, CS and GB (based on the 
decrease in ATP content and increase in LDH leakage); 
however, only in CP-treated groups (based on LDH) and 
GB-treated groups (based on ATP and LDH) it was found 
to be statistically significant. For other drug-treated groups 
a borderline significant trend was found.
Bile acid accumulation in PCLS
The BA content in PCLS incubated for 48  h without the 
addition of the BA mix, decreased by 82–98% compared 
to the fresh slice. The addition of the BA mix to the incu-
bation medium, on the other hand, resulted in the mainte-
nance of the physiological intracellular TBA concentration 
in PCLS after 48 h of incubation (Fig. 2a). The composi-
tion of the BA pool in PCLS incubated for 48 h with BA 
was only slightly different from that in fresh PCLS. For 
example, the concentration of GCA and GDCA was some-
what higher in slices incubated with the BA mix for 48 h 
compared to the fresh tissue, whereas the concentration of 
TCA and TDCA was lower in incubated PCLS compared to 
the non-incubated PCLS. In PCLS incubated without BA 
the total amount of these 8 BA in the slices was decreased 
by more than 90%, but the composition only changed to a 
minor extent (Fig. 2a, b).
The intracellular TBA concentration significantly 
increased in PCLS treated with CP, CS or GB in the pres-
ence of BA in a dose-dependent manner (Fig.  3). PCLS 
treated with the drug alone without BA, however, did not 
show a significant increase in TBA concentration, stressing 
the importance of the addition of the BA mix to the model. 
The concentrations of all eight BA measured individually 
increased after the treatment with the cholestatic drugs in 
the presence of BA (Table 2; Fig. 2d). The variation in the 
concentrations of individual BA between rats was high. 
However, the concentrations of every BA increased within 
every rat upon the drug treatment. The total concentration 
of the eight tested BA as measured by LC/MS in PCLS 
upon drug + BA-treatment was lower than the TBA con-
centration measured by the enzymatic assay, which can be 
due to the fact that some BA, such as muricholic acid, as 
well as sulfate and glucuronide conjugates of BA were not 
measured by LC/MS.
When incubated in the presence of BA, the relative 
abundance of the eight tested bile acids was similar in 
the CS5 + BA- and GB180 + BA-treated groups in com-
parison to the control, with the exception of CDCA, which 
increased 9 times upon drug exposure (Fig. 2d). The rela-
tive abundance of TCDCA and GCDCA was elevated upon 
CP36 + BA treatment (from 5 to about 20%), whereas that 
of TCA and GCA decreased (from 80% to about 45%) 
Fig. 1  ATP content of PCLS after 48-h incubation (a–c) and LDH 
leakage from PCLS to incubation medium after 48-h incubation (d–f) 
with different drugs, in the absence (gray bars) or presence (black 
bars) of BA. ATP content is expressed in absolute values. LDH leak-
age is expressed as relative values to the control without BA. Graphs 
represent the mean values ± SEM of 4–5 experiments, using 3 PCLS 
for each group in every experiment. p values for interaction effects 
BA*drug are shown
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compared to the control. Furthermore, the relative abun-
dance of CDCA increased four-fold, and of GDCA and 
TDCA increased 1.8- and 2.7-fold, respectively, in PCLS 
treated with CP36 + BA compared to the control (Table 2).
Exposure of PCLS to CS5 or GB180 in the absence 
of BA resulted in a small increase in the cumulative con-
centration of the tested BA (Fig.  2c). Surprisingly, the 
cumulative concentration of the eight tested BA in PCLS 
after CP36-treatment was lower compared to the non-
treated control (Fig. 2c). However, this phenomenon was 
not shown with the measurement of TBA concentration, 
where the concentration of TBA in PCLS was slightly 
higher in CP36-treated group compared to the control. 
No major changes occurred in the relative abundance of 
Fig. 2  Concentration of eight different BA (GCA, TCA, TCDCA, 
TDCA, GCDCA, GDCA, CDCA, DCA) in fresh PCLS and in PCLS 
incubated for 48 h with or without BA, expressed in absolute values 
(a) or in percentage of total BA (b). Concentration of eight different 
BA in PCLS incubated for 48 h with the solvent DMSO or one of the 
cholestatic drugs CP36, CS5, GB180 in the absence (c) or presence 
(d) of BA. Data are expressed in absolute values. Graphs represent 
mean values ± SEM of 10–11 experiments for a, b and 3–5 experi-
ments for c, d, using 3 PCLS for each group in every experiment
Fig. 3  TBA content of PCLS after 48-h incubation with CP (a), CS 
(b) or GB (c), in the absence (gray bars) or presence (black bars) of 
BA. TBA content is expressed in relative values to the respective con-
trol (0.16 and 1.48 nmol/mg protein for the control without or with 
BA, respectively). Graphs represent the mean values ± SEM of 4–5 
experiments, using 3 PCLS for each group in every experiment. p 
values for a dose-dependent increase in TBA content in BA + drug-
treated groups are shown
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the different BA upon PCLS exposure to CP36, CS5 or 
GB180 alone.
Gene expression
Changes in the expression of genes known to be involved 
in cholestasis, such as Bsep, Ntcp and Fxr have been inves-
tigated. NTCP is responsible for the basolateral uptake of 
bile acids, whereas BSEP is responsible for their efflux to 
the bile canaliculi on the apical side of hepatocytes. BA 
significantly decreased Ntcp gene expression to 60% in 
PCLS after 48 h of incubation. This effect of BA on Ntcp 
expression is known and has been described before. Ntcp 
gene expression in PCLS was significantly and strongly 
decreased to ca. 10% of the value of the controls after incu-
bation with CP36, CS5 and GB180 treatment alone and was 
not further decreased in the presence of BA (Fig. 4b). Bsep 
gene expression showed some variation between and within 
experimental groups, and was significantly decreased in the 
drug alone-treated groups when all experiments were taken 
altogether, but not in the group drug + BA (Fig. 4a).
Fxr is thought to be a master regulator of BA homeo-
stasis, acting on BA synthesis, conjugation and transport. 
In our study, Fxr expression was significantly downreg-
ulated by 20% in PCLS incubated with the BA mix for 
48  h, with a further stronger decrease in PCLS treated 
with CP, CS or GB (Fig. 4c), with no difference between 
with and without BA.
Correlation analysis
The decrease in viability (based on ATP content) of 
PCLS upon the exposure to CP and CS in combination 
with BA correlated with an increase in intracellular levels 
of BA, whereas no significant correlation was observed 
in the GB-treated groups (Fig. 5). The same results were 
obtained from the correlation analysis between LDH 
leakage and TBA content.
Table 2  Concentration and absolute amount of eight different BA in PCLS incubated for 48 h with the solvent DMSO or one of the cholestatic 
drugs CP36, CS5, GB180 ATP in the presence of BA
Data are expressed in absolute values. Table represents mean values ± SD (% of total) of 10–11 experiments for DMSO group and 3–5 experi-
ments for drug-treated groups, using 3 PCLS for each group in every experiment
pmol/mg protein DMSO + BA CP36 + BA CS 5 + BA GB 180 + BA
DCA 1.4 ± 1.3 (0.8%) 3.9 ± 2.8 (0.6%) 7.5 ± 8.3 (1.3%) 5.7 ± 8.3 (1%)
CDCA 0.3 ± 0.7 (0.1%) 4.0 ± 5.1 (0.5%) 8.1 ± 10.8 (1.1%) 6.7 ± 11.0 (1.2%)
GDCA 20.2 ± 11.8 (8.5%) 80.8 ± 4.7 (15.5%) 61.1 ± 38.3 (9.4%) 82.0 ± 23.0 (6.7%)
GCDCA 6.6 ± 3.8 (2.9%) 60.7 ± 13.4 (10.7%) 28.4 ± 24.9 (4.7%) 16.2 ± 9.0 (1.8%)
TDCA 13.5 ± 7.0 (6.0%) 83.8 ± 1.5 (16.3%) 38.6 ± 23 (6.2%) 56.2 ± 15.6 (5.1%)
TCDCA 4.9 ± 3.3 (2.2%) 60.2 ± 14.2 (10.4%) 29.0 ± 28.9 (4.3%) 30.3 ± 28.3 (4.2%)
TCA 41.4 ± 23.1 (16.5%) 64.5 ± 16.0 (12.1%) 90.2 ± 42.7 (14.4%) 235.8 ± 69.2 (13.8%)
GCA 156.5 ± 73.9 (63.0%) 180.3 ± 45.4 (33.8%) 364.3 ± 149.5 (58.6%) 1275.6 ± 454.7 (66.2%)
Total 245.0 ± 118.3 (100%) 538.1 ± 93.4 (100%) 627.2 ± 260.5 (100%) 1708.5 ± 448.1 (100%)
Fig. 4  Gene expression of Bsep (a), Ntcp (b) and Fxr (c) normalized 
to the housekeeping gene Gapdh. Data expressed as relative values 
compared to the 48-h control without BA. Graphs represent mean 
values ± SEM of 3–4 experiments, using 3 PCLS for each group in 
every experiment. p values for a comparison between control and all 
drug-treated groups in the absence and presence of BA are shown
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Discussion
In this study rat PCLS were verified as a model to study 
drug-induced cholestasis (DIC) and pathological pro-
cesses related to DIC using several biomarkers. Three 
drugs known to induce cholestasis were used as model 
compounds: chlorpromazine, cyclosporine A and gliben-
clamide (Stieger 2010) in the presence of a physiologi-
cal bile acid mix. Earlier PCLS were used as a model to 
study early transcriptional changes associated with chol-
estasis using mouse and human liver tissue showing gene 
expression profiles related to pathological changes asso-
ciated with cholestasis (Szalowska et  al. 2013; Vatakuti 
et al. 2016). Here we suggest for the first time that these 
drugs cause cholestatic effects as they are more toxic in 
the presence of BA in rat PCLS and induce changes in 
the intracellular bile acid concentration and composition.
The presence of BA in their physiological concentra-
tions and ratios may increase the validity of an in  vitro 
model for DIC studies. For example, incubation of mouse 
PCLS with cholestatic drugs alone did not result in the 
elevation in intracellular BA concentration (Szalowska 
et al. 2013). Moreover, in our study we showed that with-
out the addition of BA, PCLS excreted most of them dur-
ing incubation, whereas the incubation of PCLS with the 
BA mix resulted in the maintenance of the physiological 
concentrations of BA in PCLS after 48 h of incubation. 
The observed shift to glycine conjugates after the incu-
bation with the BA mix might be due to the small dif-
ference between the composition of the BA mix (which 
was based on the portal vein BA concentrations) and tis-
sue values, as well as the more active production of gly-
cine conjugates of BA during incubation compared to the 
production of tauroconjugates. This higher production 
of glycine conjugates might be explained by the higher 
substrate availability of glycine compared to the tau-
rine precursor (L-cysteine) in the medium (http://www.
thermofisher.com/) (Penttilä 1990). In addition, a shift 
between taurine and glycine conjugation was also found 
before in rats fed diet with different supplements (Park 
et al. 1999).
The secondary bile acids, such as DCA and LCA, are 
considered to be the most toxic BA due to their lipophilicity 
and, therefore, are important in the progression of bile acid-
induced hepatic injury (Li and Chiang 2011; Schadt et al. 
2016; Yang et  al. 2013). However, they are not produced 
in the liver but formed in the intestinal track by anaerobic 
and/or aerobic bacteria (Alnouti 2009). Since in vitro liver 
models usually do not include the liver–intestine interac-
tion part, the addition of these secondary BA to the BA mix 
is necessary to study the effects of these toxic BA and the 
shifts in ratios of certain BA during cholestasis.
High concentrations of CP, CS and GB in combination 
with the BA mix decreased the viability of PCLS, which 
correlated for CP and CS with the increase in the intracel-
lular concentrations of BA. The increase in the total con-
centration of BA upon the exposure to cholestatic drugs as 
well as changes in the fractions of the eight most prevalent 
BA in the body has been analyzed. We showed that all three 
cholestatic drugs CP, CS and GB caused a dose-depend-
ent increase in BA in PCLS, but this resulted in different 
profiles of accumulated BA. For example, CP-treatment 
increased the relative abundance of CDCA and its conju-
gates GCDCA and TCDCA, as well as DCA conjugates 
GDCA and TDCA, whereas the abundance of GCA and 
TCA was decreased. CS and GB, on the other hand, did not 
significantly change the composition of the BA pool with 
respect to CA and CDCA conjugates, but the relative abun-
dance of CDCA itself and that of the secondary BA DCA 
were increased. DCA and CDCA are known to be more 
toxic than the other measured BA due to their lipophilicity 
and, therefore, the increase in their intracellular concentra-
tion in PCLS treated with cholestatic drugs, might at least 
partly be responsible for the toxicity observed. The differ-
ences in the composition of the intracellular BA pool fol-
lowing the exposure to different cholestatic drugs may be 
explained by the different abilities of the individual drugs 
to inhibit the BSEP-mediated transport of certain BA (Yang 
et al. 2013).
In this study, we did not find a threshold value of the 
intracellular concentration of TBA above which the viabil-
ity of PCLS decreases. Different drugs decreased PCLS 
Fig. 5  Correlation between ATP and TBA content of PCLS treated with CP (a), CS (b) or GB (c) in combination with BA. Graphs represent 
mean values ± SEM of 4–5 experiments, using 3 PCLS for each group in every experiment. p values and R values are shown
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viability at different intracellular levels of BA, showing 
some variability also within their own group. These data 
might indicate that the toxicity depends not on the elevation 
in the total BA, but more likely is attributed to the increase 
in the concentration and relative abundance of certain toxic 
BA, such as LCA, DCA and its conjugates and CDCA. We 
have shown the increase in the relative abundance of DCA, 
DCA conjugates and CDCA upon the treatment with toxic 
concentrations of cholestatic drugs. However, to show the 
correlation between the viability of PCLS and the increase 
in the concentration of these BA (with the possibility to 
find a threshold value), further analysis with various con-
centrations of drugs needs to be performed.
Previous studies on sandwich-cultured hepatocytes 
(SCH) demonstrated higher toxicity of CS and GB in the 
presence than in the absence of BA. In our study, CS con-
centrations that led to the decrease in viability and increase 
in intracellular BA concentrations were two- to threefolds 
lower (Chatterjee et al. 2014b; Ogimura et al. 2011; Oorts 
et  al. 2016) than that found with rat or human SCH. In 
PCLS,  IC50 values of CP and GB in the presence of BA 
were similar to (for CP) or 1.5–3-folds higher (for GB) 
than those in rat SCH (Chatterjee et  al. 2014b; Ogimura 
et al. 2011). Nevertheless, none of these studies measured 
BA accumulation in hepatocytes to confirm BA-dependent 
hepatotoxicity. Even though Ansede et al. showed the pos-
sibility to study intracellular accumulation of BA upon CS 
and GB treatment in SCH, further studies using other toxic-
ity parameters to test BA-dependent toxicity have not been 
performed (Ansede et al. 2010). Future studies comparing 
PCLS to other in  vitro models and using PCLS model to 
test drugs that were not recognized as cholestatic by these 
other models would be of interest.
Elevated BA levels are considered to be one of the key 
triggers in DILI development. However, in many cases, 
altered transporter functions coincide with other mecha-
nisms of cytotoxicity and liver injury. The ability of BA to 
trigger cytotoxic effects has been shown in various stud-
ies (Attili et al. 1986; Palmeira and Rolo 2004; Rolo et al. 
2000; Woolbright et  al. 2015). For example, certain BA 
was shown to impair mitochondrial function by altering the 
transmembrane potential and mitochondrial permeability 
transition (Rolo et  al. 2000). Moreover, a recent study on 
primary human hepatocytes (PHH) showed that exposure 
of PHH to high concentration of GCDCA leads to necro-
sis. However, the BA concentrations used in this study far 
exceeded the serum concentrations measured in cholestatic 
patients (Woolbright et al. 2015). Serum BA values are not 
always representative for the intracellular BA concentra-
tions, since they represent the net effect of the uptake of BA 
into hepatocytes, which can be also inhibited without chol-
estasis, and the basolateral efflux of BA due to high intra-
cellular concentrations during cholestasis.
In our study, low non-toxic doses of cholestatic drugs 
moderately increased the intracellular BA concentration in 
PCLS, possibly indicating inhibition of the excretion of BA 
by BSEP. However, high doses of drugs are likely to pro-
voke various other toxicological mechanisms aside BSEP 
inhibition that contribute to the overall toxicity observed. 
For example, high doses of CP, CS and GB without the 
presence of BA in the medium slightly decreased ATP lev-
els and increased LDH leakage in PCLS, which cannot be 
explained by the small increase in intracellular BA levels 
as they are still far below the physiological levels, repre-
sented by the t = 0 samples and the values at 48-h incuba-
tion with BA (Figs.  2c, d, 3). Therefore, while there are 
indications that BSEP inhibition and as a consequence BA 
accumulation are important players in DILI initiation, the 
progression of liver injury likely also involves other key 
adverse events that lead to the disturbance of the normal 
cell physiology.
Fxr is a member of the nuclear receptor subfamily and 
is directly involved in BA homeostasis (Claudel et al. 2005; 
Modica et al. 2010; Schadt et al. 2016). It was reported that 
Fxr regulates both bile acid synthesis and transport. For 
example, activation of Fxr by BA leads to the downregula-
tion of Cyp7a1 and Cyp8b1 involved in BA synthesis (Li 
and Chiang 2011; Schadt et al. 2016). Moreover, activation 
of Fxr by an intracellular increase in BA concentration sup-
presses the hepatic influx transporters NTCP and OATP 
and upregulates the major bile acid efflux transporter 
BSEP. This downstream cascade of responses is playing a 
protective role directed on the reduction of intracellular BA 
concentration and, as a result, prevention of the bile acid-
induced cytotoxicity.
Incubation of PCLS with the BA mix resulted in the 
slight downregulation of Fxr gene. This may be due to 
the increased levels of GDCA as it was shown that GDCA 
decreased the expression of Fxr in human cholangiocar-
cinoma cells in vitro (Dai et al. 2011). Moreover, induced 
expression of human and mouse Fxr by Fxr agonists 
GW4064 and CDCA was reversed by LCA or GDCA (Dai 
et al. 2011; Yu et al. 2002). The secondary BA, DCA and 
LCA have a higher affinity to the Fxr receptor than, for 
example CDCA, that increases the expression of Fxr and 
activates it (Dai et  al. 2011; Paumgartner et  al. 2004; Yu 
et  al. 2002). In our study, the concentration of DCA and 
its conjugates in PCLS incubated with the BA mix was 
more than 100-fold higher than in the control slices with-
out the addition of BA that might explain the difference in 
Fxr expression and activation between the two groups. This 
also indicates that the regulation of Fxr expression and its 
target genes depends on a defined balanced of agonists and 
antagonists in the milieu.
Exposure of PCLS to CP, CS or GB resulted in a very 
strong downregulation of Fxr, which is in line with previous 
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studies on mouse and human PCLS that demonstrated FXR 
downregulation by cholestatic compounds (Szalowska et al. 
2013; Vatakuti et  al. 2016). Regulation of Fxr in hepato-
cytes and enterocytes is a complex process of a multifacto-
rial nature that can be also influenced by other factors not 
directly involved in bile acid homeostasis. For example, a 
given drug can directly disrupt Fxr function or can influ-
ence its expression indirectly by triggering inflammatory 
and cytotoxic processes in the liver (Rodrigues et al. 2014; 
Szalowska et  al. 2013). Various cholestatic drugs, includ-
ing CP and CS, have been shown to cause ER stress, oxi-
dative stress, apoptosis, trigger inflammatory responses and 
influence β-oxidation in the liver (Anthérieu et  al. 2013; 
Szalowska et al. 2015; Vatakuti et al. 2016). These patho-
logical processes, in turn, can lead to the downregulation 
of Fxr, as well as other nuclear receptors (Szalowska et al. 
2013). Moreover, the concentration of secondary BA DCA 
and its conjugates increased 3 to five-folds in PCLS treated 
with cholestatic drugs that might have further contributed 
to Fxr downregulation.
The Ntcp expression in rat PCLS treated with the BA 
mix was 40% lower compared to the non-treated control, 
which is in line with previously reported data, where it 
was shown that BA negatively regulates Ntcp expression. 
The effects of BA on Ntcp are thought to be mediated via 
Fxr stimulation and, as a result, SHP pathway activation 
(Modica et  al. 2010; Schadt et  al. 2016). Furthermore, 
BA can increase SHP stability by inhibiting its proteaso-
mal degradation in an extracellular signal-regulated kinase 
(ERK)-dependent manner (Miao et al. 2009). In our study 
Ntcp downregulation by the BA mix could be of Fxr-
dependent or -independent manner, since Fxr expression 
was also downregulated in the BA-treated group compared 
to the non-treated control. The Ntcp expression was shown 
to be regulated also via other signaling pathways involv-
ing transcription factors, such as HNF4α, HNF3β, HNF1α 
or the glucocorticoid receptor (Kosters and Karpen 2008; 
Matsubara et  al. 2012). Moreover, Ntcp expression in the 
non-treated control, on the other hand, could have been 
upregulated due to the low concentrations of BA present 
in the system. All tested cholestatic drugs induced a down-
regulation of Ntcp expression, which can be considered as 
an adaptive response to the increase in intracellular concen-
tration of BA. Moreover, the three drugs themselves were 
found to downregulate Ntcp in the absence of BA.
Inhibition of BSEP is thought to play a crucial role in 
drug-induced cholestasis (Vinken et  al. 2013; Yang et  al. 
2013). Cholestatic drugs can directly inhibit BSEP activity 
by binding to the transporter protein in a competitive man-
ner (Kosters and Karpen 2008; Pauli-Magnus and Meier 
2006; Stieger 2010). Some previous studies have shown 
that cholestatic drugs may also reduce the expression of 
Bsep mRNA in mouse and human PCLS (Szalowska et al. 
2013; Vatakuti et al. 2016), whereas another study on rats 
did not reveal any changes in Bsep expression after CS 
and sirolimus treatment (Bramow et al. 2001). In our study 
Bsep expression was reduced in slices treated with CP (with 
or without BA mix) or CS-alone. GB treatment, however, 
did not result in any significant changes in Bsep mRNA 
levels. Moreover, it is thought that genetic polymorphism 
in the expression of BSEP or mutations in this transporter 
increase the risk of the development of DIC and is associ-
ated with idiosyncratic cholestatic episodes in some of the 
patients taking a potentially cholestatic drug (Chalasani 
and Björnsson 2010).
In summary, we showed that rat PCLS exposed to chole-
static drugs in the presence of a physiological BA mix 
reflect various changes associated with cholestasis, such as 
decrease in hepatocyte viability, accumulation of BA and 
changes in the expression of genes known to play a role 
in cholestasis. Therefore, we believe that PCLS represent 
a physiological and valuable model to identify potential 
cholestatic compounds and elucidate mechanisms under-
lying DIC and DILI. The toxicity of cholestatic drugs was 
correlated with the accumulation of BA, and especially 
DCA and CDCA and their conjugates, but to a different 
extent for the different drugs, indicating that BA toxicity is 
not the only cause for the toxicity of cholestatic drugs. This 
study was performed with rat PCLS and, therefore, needs to 
be further verified with human PCLS, to avoid species-spe-
cific differences with respect to the cholestatic action of the 
tested compounds. Moreover, our study supports the use of 
a combination of several biomarkers to identify the chole-
static potential of a drug, since every one of them apart 
might not be sufficiently predictive or specific.
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